Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1879 0844 "

Sökning: L773:1879 0844

Sortera/gruppera träfflistan
  • Adamsson, Lisa, et al. (författare)
  • Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index.
  • 2021
  • Ingår i: European journal of heart failure. - 1879-0844. ; 23:10, s. 1662-1672
  • Tidskriftsartikel (refereegranskat)abstract
    • In heart failure with reduced ejection fraction (HFrEF), there is an 'obesity paradox', where survival is better in patients with a higher body mass index (BMI) and weight loss is associated with worse outcomes. We examined the effect of a sodium-glucose co-transporter 2 inhibitor according to baseline BMI in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF).Body mass index was examined using standard categories, i.e. underweight (<18.5 kg/m2 ); normal weight (18.5-24.9 kg/m2 ); overweight (25.0-29.9 kg/m2 ); obesity class I (30.0-34.9 kg/m2 ); obesity class II (35.0-39.9 kg/m2 ); and obesity class III (≥40 kg/m2 ). The primary outcome in DAPA-HF was the composite of worsening heart failure or cardiovascular death. Overall, 1348 patients (28.4%) were under/normal-weight, 1722 (36.3%) overweight, 1013 (21.4%) obesity class I and 659 (13.9%) obesity class II/III. The unadjusted hazard ratio (95% confidence interval) for the primary outcome with obesity class 1, the lowest risk group, as reference was: under/normal-weight 1.41 (1.16-1.71), overweight 1.18 (0.97-1.42), obesity class II/III 1.37 (1.10-1.72). Patients with class I obesity were also at lowest risk of death. The effect of dapagliflozin on the primary outcome and other outcomes did not vary by baseline BMI, e.g. hazard ratio for primary outcome: under/normal-weight 0.74 (0.58-0.94), overweight 0.81 (0.65-1.02), obesity class I 0.68 (0.50-0.92), obesity class II/III 0.71 (0.51-1.00) (P-value for interaction = 0.79). The mean decrease in weight at 8 months with dapagliflozin was 0.9 (0.7-1.1) kg (P < 0.001).We confirmed an 'obesity survival paradox' in HFrEF. We showed that dapagliflozin was beneficial across the wide range of BMI studied.ClinicalTrials.gov NCT03036124.
  • Agvall, Björn, et al. (författare)
  • The benefits of using a heart failure management programme in Swedish primary healthcare
  • 2013
  • Ingår i: European Journal of Heart Failure. - : Oxford University Press (OUP): Policy B. - 1388-9842 .- 1879-0844. ; 15:2, s. 228-236
  • Tidskriftsartikel (refereegranskat)abstract
    • Heart failure (HF) is a common condition with which high mortality, morbidity, and poor quality of life are associated. It has previously been shown that use of HF management programmes (HFMPs) in HF clinics can be beneficial. The purpose of this study was to evaluate if the use of HFMPs also has beneficial effects on HF patients in primary healthcare (PHC). less thanbrgreater than less thanbrgreater thanThis is a randomized, prospective, open-label study including 160 patients from five PHC centres with systolic HF and a mean age of 75 years (standard deviation 7.8). In the intervention group, an intensive follow-up was performed by HF nurses and physicians providing information and education about HF and the optimization of HF treatment according to recognized guidelines. There was a significant improvement of composite endpoints in the intervention group. Significantly more patients with reduced N-terminal pro brain natriuretic peptide (P 0.012), improved cardiac function (P 0.03), fewer healthcare contacts (P 0.04), and fewer emergency room visits and admittances (P 0.0002 and P 0.03, respectively) could be seen in the intervention group when compared with the control group. less thanbrgreater than less thanbrgreater thanThe use of a HFMP in a PHC setting was found to have beneficial effects in terms of reducing the number of healthcare contacts and hospital admissions, and improving cardiac function in patients with systolic HF, even if the result should be interpreted with caution. It can therefore be recommended that HFMPs should be used in PHC.
  • Aimo, Alberto, et al. (författare)
  • Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology
  • 2022
  • Ingår i: European Journal of Heart Failure. - : WILEY. - 1388-9842 .- 1879-0844.
  • Forskningsöversikt (refereegranskat)abstract
    • In patients with heart failure, the beneficial effects of drug and device therapies counteract to some extent ongoing cardiac damage. According to the net balance between these two factors, cardiac geometry and function may improve (reverse remodelling, RR) and even completely normalize (remission), or vice versa progressively deteriorate (adverse remodelling, AR). RR or remission predict a better prognosis, while AR has been associated with worsening clinical status and outcomes. The remodelling process ultimately involves all cardiac chambers, but has been traditionally evaluated in terms of left ventricular volumes and ejection fraction. This is the second part of a review paper by the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology dedicated to ventricular remodelling. This document examines the proposed criteria to diagnose RR and AR, their prevalence and prognostic value, and the variables predicting remodelling in patients managed according to current guidelines. Much attention will be devoted to RR in patients with heart failure with reduced ejection fraction because most studies on cardiac remodelling focused on this setting.
  • Aimo, Alberto, et al. (författare)
  • Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T
  • 2020
  • Ingår i: European Journal of Heart Failure. - 1388-9842 .- 1879-0844. ; 22:11, s. 2078-2088
  • Tidskriftsartikel (refereegranskat)abstract
    • Aims N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-TnT) and soluble suppression of tumorigenesis-2 (sST2) predict outcome in chronic heart failure (HF). We assessed the influence of age on circulating levels and prognostic significance of these biomarkers. Methods and results Individual data from 5301 patients with chronic HF and NT-proBNP, hs-TnT, and sST2 data were evaluated. Patients were stratified according to age: <60 years (n = 1332, 25%), 60-69 years (n = 1628, 31%), 70-79 years (n = 1662, 31%), and >= 80 years (n = 679, 13%). Patients (median age 66 years, 75% men, median left ventricular ejection fraction 28%, 64% with ischaemic HF) had median NT-proBNP 1564 ng/L, hs-TnT 21 ng/L, and sST2 29 ng/mL. Age independently predicted NT-proBNP and hs-TnT, but not sST2. The best NT-proBNP and hs-TnT cut-offs for 1-year and 5-year all-cause and cardiovascular mortality and 1- to 12-month HF hospitalization increased with age, while the best sST2 cut-offs did not. When stratifying patients according to age- and outcome-specific cut-offs, this stratification yielded independent prognostic significance over NT-proBNP levels only, or the composite of NT-proBNP and hs-TnT, and improved risk prediction for most endpoints. Finally, absolute NT-proBNP, hs-TnT, and sST2 levels predicted outcomes independent of age, sex, left ventricular ejection fraction category, ethnic group, and other variables. Conclusions Soluble ST2 is less influenced by age than NT-proBNP or hs-TnT; all these biomarkers predict outcome regardless of age. The use of age- and outcome-specific cut-offs of NT-proBNP, hs-TnT and sST2 allows more accurate risk stratification than NT-proBNP alone or the combination of NT-proBNP and hs-TnT.
  • Alehagen, Urban, et al. (författare)
  • A clinician’s experience of using the Cardiac Reader NT-proBNP point-of-care assay in a clinical setting
  • 2008
  • Ingår i: European Journal of Heart Failure. - : Institutionen för medicin och hälsa. - 1388-9842 .- 1879-0844. ; 10:3, s. 260-266
  • Tidskriftsartikel (refereegranskat)abstract
    • The evaluation of natriuretic peptides has become increasingly valuable in a clinical setting, where information is often needed promptly. Objectives: To compare the usefulness of the recently released Roche Cardiac Reader ® NT-proBNP assay against the Roche Elecsys® NT-proBNP laboratory system in a clinical setting. Design and Results: Blood samples from 440 patients admitted for acute coronary syndromes, worsening of heart failure, or as policlinic heart failure patients were evaluated. The relation between the assays was analysed and the diagnostic concordance calculated. A good correlation was found between the assays (r=0.96, 95% CI: 0.94-0.97) with a diagnostic concordance of 0.93. A separate analysis was performed in the range where most clinical decisions are made (60-3000 ng/L), with a diagnostic concordance of 88%. The usefulness in a clinical setting where time is important was high. Conclusion: The Roche Cardiac Reader® NT-proBNP assay has been evaluated in a clinical setting. The point-of-care method shows good results, although with a restricted analytical range compared with the reference.
  • Ambrosy, A. P., et al. (författare)
  • Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial
  • 2012
  • Ingår i: European journal of heart failure. - 1879-0844. ; 14:3, s. 302-311
  • Tidskriftsartikel (refereegranskat)abstract
    • AIMS: Abnormal liver function tests (LFTs) are common in ambulatory heart failure (HF). The aim of this study was to characterize abnormal LFTs during index hospitalization. METHODS AND RESULTS: A post-hoc analysis was carried out of the placebo group of the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan) trial, which enrolled patients hospitalized for HF with an ejection fraction (EF) 34 IU/L), alanine transaminase (ALT, >34 IU/L), alkaline phosphatase (AP, >123 IU/L),gamma-glutamyl transferase (GGT, >50 IU/L), and total bilirubin (T Bili, >1.2 mg/dL) were measured at baseline, discharge/day 7, and post-discharge. Co-primary endpoints were all-cause mortality (ACM) and cardiovascular mortality or first HF hospitalization (CVM + HFH). Study participants had a mean age of 65.6 +/-12.0 years, were mostly male, reported high prevalences of medical co-morbidities, and were well treated with evidence-based therapies. Baseline LFT abnormalities were common (ALB 17%, AST 21%, ALT 21%, AP 23%, GGT 62%, and T Bili 26%). Abnormal T Bili was the only marker to decrease substantially from baseline (26%) to discharge/day 7 (19%). All LFTs, except AP, improved post-discharge. Lower baseline ALB and elevated T Bili were associated with higher rates of ACM, and in-hospital decreases in ALB and increases in T Bili were associated with higher rates of both ACM and CVM + HFH. CONCLUSION: LFT abnormalities are common during hospitalization for HF in patients with reduced EF and were persistent at discharge. Baseline and in-hospital changes in ALB and T Bili provide additional prognostic value.
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (373)
forskningsöversikt (7)
recension (1)
Typ av innehåll
refereegranskat (316)
övrigt vetenskapligt (65)
Jaarsma, Tiny (73)
Lund, LH (51)
Swedberg, Karl, 1944 (40)
Lund, Lars H. (33)
Dahlström, Ulf (33)
van Veldhuisen, Dirk ... (28)
visa fler...
Ponikowski, Piotr (26)
Filippatos, Gerasimo ... (26)
Anker, Stefan D (26)
Dickstein, Kenneth (24)
Metra, Marco (23)
Chioncel, Ovidiu (22)
Savarese, G (21)
Savarese, Gianluigi (20)
Coats, Andrew J. S. (20)
Piepoli, Massimo F. (20)
Ruschitzka, Frank (19)
Ruschitzka, F. (18)
Coats, AJS (17)
Metra, M (17)
Seferovic, Petar (17)
Linde, C (16)
Lainscak, M (16)
McMurray, John J V (16)
Strömberg, Anna (15)
Hill, Loreena (15)
Mullens, Wilfried (15)
Seferovic, PM (15)
Anker, SD (14)
Voors, Adriaan A. (14)
Piepoli, MF (14)
Filippatos, G (14)
Rosano, Giuseppe M. ... (14)
Seferovic, Petar M. (12)
de Boer, Rudolf A. (12)
Ben Gal, Tuvia (12)
Celutkiene, Jelena (11)
Volterrani, Maurizio (11)
Moura, Brenda (11)
Rosano, Giuseppe (11)
Benson, Lina (11)
Hillege, Hans L. (11)
Bauersachs, J. (11)
Ponikowski, P (11)
Lindmark, K (11)
Boman, Kurt (10)
Thum, Thomas (10)
Mueller, Christian (10)
Mebazaa, Alexandre (10)
Dahlstrom, U (10)
visa färre...
Karolinska Institutet (150)
Linköpings universitet (125)
Göteborgs universitet (67)
Uppsala universitet (58)
Umeå universitet (29)
Lunds universitet (28)
visa fler...
Jönköping University (12)
Örebro universitet (5)
Kungliga Tekniska Högskolan (4)
Högskolan Dalarna (3)
Linnéuniversitetet (2)
Stockholms universitet (1)
Högskolan i Skövde (1)
Högskolan i Halmstad (1)
RISE (1)
Karlstads universitet (1)
Röda Korsets Högskola (1)
visa färre...
Engelska (381)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (209)
Samhällsvetenskap (6)
Naturvetenskap (1)
Lantbruksvetenskap (1)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy